BioMarin Pharmaceutical Inc. (BMRN) Rated Overweight at Wells Fargo Despite Voxzogo Phase 2 Study Discontinuations

We recently compiled a list of the 10 Quality Value Stocks Likely to Make a Comeback According to Analysts. BioMarin Pharmaceutical Inc. is among the best value stocks to invest in.

TheFly reported on March 16 that Wells Fargo maintained an Overweight rating on BMRN with a $75 price target. The firm noted that BioMarin discontinued three Phase 2 Voxzogo studies in Turner Syndrome, SHOX-deficiency, and ACAN-deficiency due to cases of Slipped Capital Femoral Epiphysis observed in investigator-sponsored trials. Wells Fargo views the safety risk as specific to certain indications rather than the drug’s mechanism, and considers BMRN’s outlook less dependent on Voxzogo. The firm indicated it remains supportive and sees the shares as a buying opportunity in the event of price weakness.

On March 12, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reported positive new results from ongoing clinical trials and real-world studies of Voxzogo (vosoritide) in children with achondroplasia. The findings highlight the benefits of early treatment, demonstrating sustained multi-year growth improvements, enhanced body proportionality, and increased arm span compared to untreated children.

Analyses also showed durable height gains, stable arm-to-height ratios, and significant improvements in body mass index for those who began treatment before age two. Additional real-world data from patients in Japan, Europe, and the U.S. will be presented at the 2026 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting in Baltimore, reinforcing the established efficacy and safety profile of Voxzogo.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is a biotechnology company that develops and commercializes therapies for rare genetic diseases, including enzyme‑replacement and gene therapies, improving treatment options for patients with serious, often life‑limiting conditions.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.